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Abstract: Clinical trials have advanced the treatment of multiple sclerosis (MS) by
demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review
discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS
continue to increase, patients in modern MS trials present earlier and with milder disease
compared with historic MS populations. While placebo-controlled trials for some questions
may still be relevant, DMT trials in relapsing–remitting MS (RRMS) are no longer ethical. The
replacement of the placebo arm by an active comparator arm in trials have raised the cost of
trials by requiring larger sample sizes to detect on-study changes in treatment effects. Efforts
to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on
sensitive magnetic resonance imaging measures of disease activity. In trials for progressive
forms of MS (PMS), the lack of sensitive outcome measures that can be used in shorter-term
trials have delayed the development of effective treatments. Recent shifting of the focus to
advancing trials in PMS has identified paraclinical outcome measurements with improved
potential, and the testing of agents for neuroprotection and remyelination is in progress.

Keywords: multiple sclerosis, clinical trials, trial design, diagnostic criteria, outcome measure,
progressive multiple sclerosis
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Introduction
The advancement of new therapeutic agents for
multiple sclerosis (MS) relies on well-designed
clinical trials to establish their safety and efficacy.
Over the last two decades, clinical trials in MS
have established a success rate of 27%, defined as
passing phase I, II, III and United States Food
and Drug Administration (US FDA) approval,
almost tripling the overall industry rate of 10%.1
As a result of now having 15 approved diseasemodifying therapies (DMTs) for relapsing–remitting MS (RRMS), there is a greater challenge to
improve the existing options and to achieve prolonged remission. The increased availability of
treatment along with revisions in the diagnostic
criteria have changed the clinical trial population
and restricted the implementation of placebo-controlled trials. At the same time, an increased
understanding of the pathophysiology and natural
history of the disease have spurred the development of new outcome measurements and refinement of existing metrics. Despite numerous
successes in advancing therapies for RRMS,
journals.sagepub.com/home/tan

similar progress has not been achieved for patients
with progressive forms of MS (PMS), and previously failed trials in PMS have delineated the challenges that must be overcome to develop
treatments for PMS. The design of MS trials must
take its dynamic landscape into consideration and
account for the differences between modern and
historical trials. This article will review the changing characteristics of MS trial patients, the shift
from placebo-controlled trials to active comparator studies, and traditional and new outcome
measurements. In addition, the challenges and
progress in PMS trials will be discussed.
Changes in trial populations
The characteristics of RRMS trial populations
have changed over time, largely in response to
shifting methodologies in patient diagnosis and
selection as well as the availability of multiple
treatments. Patients in recent trials are presenting
with lower disease activity and slower clinical progression.2 This is evident in the annualized relapse
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rates (ARRs) in the treatment groups from historical trials between 1993–2002 that have ranged
between 0.5 and 0.87 whereas subsequent modern-day trials have reported ARRs between 0.16
and 0.37.3 While some of the reductions in relapse
rates are likely due to the more rigid definitions in
trials used to confirm relapses, there nevertheless
appears a steady decline in the ARR over time. A
report analyzing the ARR in RRMS trials over
time demonstrated a reduction of 0.37 relapses in
the treatment arms and 0.36 in the placebo arms
over a 10-year study period.4 In addition, patients
who were relapse-free in the placebo groups of
RRMS trials experience a longer time to their first
relapse.2 The trend of MS trial patients presenting
with milder disease over time is a result of multiple
processes. In this section, we explore the changes
in the MS trial population and its implications.
Changes in diagnostic criteria
The MS diagnostic criteria and its subsequent
revisions have made it easier to diagnose the disease and this has resulted in many patients receiving an earlier diagnosis.5,6 Since the 2010 revision
of the McDonald criteria, a diagnosis of MS can
be made in a single time frame, in which lesions
on a single magnetic resonance imaging (MRI)
scan can fulfill both criteria for dissemination in
time (DIT) and dissemination in space (DIS).
This contrasts with previous criteria in which the
diagnosis required subsequent clinical presentations or MRI to fulfill DIT. The latest revision of
the McDonald criteria in 2017 further broadened the diagnostic parameters and included the
presence of oligoclonal bands in the cerebrospinal fluid to substitute for DIT when the initial
MRI findings did not fulfill this requirement.7 In
addition, cortical lesions, and symptomatic
lesions excluding the optic nerve, may now be
counted as MRI evidence of DIS or DIT. By
broadening the diagnostic criteria, more patients
are likely to be diagnosed earlier whereas they
previously would not be diagnosed by an earlier
version of the criteria.
A consequence of earlier diagnosis resulting from
changes in diagnostic criteria is that the overall
clinical course of MS appears to improve. The
average MS patient today has milder disease
compared with those diagnosed using the older
criteria. However, this may have resulted in leadtime bias, in which earlier diagnosis appears to
improve the disease course as patients take longer
2

to accumulate neurological disability. This would
lower the ARR by providing an observed time
with fewer relapses relative to the older definitions, such as the Poser criteria. This lead-time
bias would also lead to the appearance of less
virulent disease, at least in the short term.
Whether this is occurring is difficult to separate
from potential confounders such as improved
availability and efficacy of therapies.
Likewise, a portion of patients with clinically isolated syndrome (CIS) who are at high risk of
developing MS will have a diagnosis of MS under
the new criteria. The reassignment of patients
who are at a higher risk within the CIS group to
those having milder disease in the MS group
results in the improved overall prognosis of both
groups, an effect known as the Will Rogers phenomenon.8 This has been demonstrated since the
first iteration of the McDonald criteria by a retrospective analysis showing that 50% of patients
with CIS would progress into definite MS within
a year by the 2001 McDonald criteria compared
with only 20% under the previously used Poser
criteria.9 Currently, there is no evidence as to
whether the 2017 revision will select patients with
less active disease. Recently, a retrospective analysis on reaching the diagnosis of MS under the
latest revision of the McDonald criteria compared
with the 2010 revision, concluded that the 2017
revision expedites diagnosis without compromising diagnostic accuracy.10
Availability of treatment
The increasing availability of treatment for RRMS
has also affected patient enrollment in trials. With
multiple DMTs available, there are motivations
for high-risk patients not to enroll in a clinical
trial as these patients may opt to select a proven
therapy rather than enroll in a trial and risk receiving a placebo or a medication with unknown
safety or efficacy profiles. Likewise, patients currently involved in trials who experience a relapse
may be rescued and removed from the trial to
start a proven therapy, thus leaving those whose
disease activity is relatively well-controlled during
the trial period to complete the study. There are
suggestions that over time, withdrawals from
therapy have been increasing and even mandated
on the occurrence of relapses or progression, thus
reducing the opportunity to have subsequent outcome events reducing the ARR and other event
rates over the course of the study.
journals.sagepub.com/home/tan
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On the other spectrum, patients who are treatment nonresponders may be interested in seeking
new options by enrolling in a trial. However,
some trials exclude enrollment of patients with
extensive exposure to prior DMTs.11,12
Additional considerations
Other factors have been proposed to account for
the changing MS trial population. For example,
increasing physician and patient awareness of the
disease and accessibility to MRI scanning has led
to earlier diagnosis and initiation of treatment.13,14
Improved standards of care for MS and accessibility to DMTs have resulted in better overall management and thus, lower disease activity in the
overall MS population. Modern-day trials allow
patients to enroll closer to their time of diagnosis
by reducing the requirement of the number of
relapses prior to screening. Whereas most early trials required at least two relapses over the course of
2 years, many contemporary trials allow for enrollment with just one relapse over the past year. In
addition, recent trials use more stringent and
objective definitions of relapse requiring evaluation
by a neurologist and measurable increases in the
Expanded Disability Status Scale (EDSS) functional system subscores.15 Together, these changes
further substantiate the shift of the MS trial population towards milder disease activity.
Implications
The changing MS trial population complicates
the comparison of results from different studies,
especially those from different times.16 Assessing
whether one DMT is superior to another is challenging without a head-to-head comparison of
the two agents in a randomized controlled trial,
yet it is impractical to conduct head-to-head studies of all available agents. As trial patients present
with milder disease, it becomes more difficult to
generate on-study changes with traditional
designs, and therefore larger group sizes and
longer study duration are required. At the same
time, it is no longer practical to design studies
based on assumptions drawn from historic trials.
Studies that are designed and statistically powered according to findings from earlier trials may
overestimate disease activity and underestimate
the number of patients enrolled to be able to
detect treatment differences. There is a need for
more efficient designs and sensitive outcome
measurements.
journals.sagepub.com/home/tan

Trial designs
The rapid expansion of treatment options for
RRMS has led to changes in clinical trial designs
over time. The era of placebo-controlled trials to
establish new DMTs has ended due to the ethical
concerns when existing therapies are available,
and new agents are now assessed through comparative studies using established DMTs. The
increased costs of large trials and high demand for
participants have spurred the need for more efficient designs, while increased therapeutic options
calls for pragmatic studies to determine the realworld applicability. The strength and limitations
of MS trial designs are summarized in Table 1.
The ethics of placebo in RRMS trials
New treatment options for RRMS have led to the
decline of placebo-controlled trials due to the ethics and marketing concerns of performing such
studies when multiple effective therapies exist.
The 1990s saw the approval of the first MS therapies, including interferon β preparations and glatiramer acetate.17–19 These trials relied on the use
of a placebo group to demonstrate the efficacy of
the investigated agent. Subsequent pivotal phase
III trials of new therapies incorporated a placebo
group until the approval of alemtuzumab, which
in 2014 became the first US-approved agent
without comparison with a placebo.20,21 However,
the ethics of using a placebo in MS trials have
been in discussion since much earlier.
Following the availability of the first injectable
DMTs, the National MS Society organized an
international task force in 2000 to discuss and
publish proceedings on the ethical use of placebos
in MS trials, and its recommendations were further revised in 2008.22,23 The group concluded
that participation in placebo trials is still ethical for
patients who decline or fail available agents or
when established therapy is not available at the
time, such as in PMS. In countries without access
to any DMTs, placebos may also remain ethical,
but active comparator trials still seem more appropriate. Some countries, such as Brazil, will not
allow placebo-controlled trials if the trial is not
conducted in the country originating the trial. In
all cases, appropriate informed consent and information on available therapies must be provided.
Controversies exist on whether placebo trials are
justified, and despite recommendations restricting
the use of placebo in RRMS trials, subsequent
3
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Table 1. Advantages and disadvantages of MS trial designs.
Trial design

Advantages

Disadvantages

Placebo-controlled

Most rigorous test of treatment efficacy;
requires fewer participants than active
comparator trials

No longer ethical in RRMS trials due to
availability of proven therapies

Active comparator

Alternative to placebo-controlled trials
and still capable of detecting treatment
effect

Requires increased sample size
to detect significant treatment
differences

Combination

Potential to increase efficacy by
combining therapies

Increased costs and side effects
from added treatment; potentially
antagonistic interactions; increased
design complexity

Adaptive

Flexible and efficient designs to reduce
sample size, exposure to harmful or
ineffective treatment, and trial duration

Requires detailed planning and review
of interim data as well as sensitive
short-term outcome measures

Pragmatic

Real life evaluation of treatment
effectiveness; high external validity;
results are more likely to inform practice

Greater design challenges due to
heterogeneity of treatment effect;
larger sample size and duration
needed to determine effectiveness

MS, multiple sclerosis; RRMS, relapsing–remitting MS.

phase III trials of fingolimod, teriflunomide, and
dimethyl fumarate had approximately 1500 patients
exposed to placebo treatment.24 Many researchers
and organizations have taken a middle ground with
regard to using a placebo when proven therapies
are available.25 The continued use of a placebo is
backed by claims of the changing natural history of
MS and indication that data from previous placebo
groups are no longer valid.26 However, as growing
evidence surmounts to the detrimental effects of
delaying initiation of DMT for RRMS, the use of a
placebo in RRMS trials have ended.27
Active comparator designs
The past decade saw a gradual replacement of placebo designs by active comparator trials. The pivotal phase III trial of peginterferon β-1a marked
the last placebo-controlled trial of a therapeutic
agent for RRMS.28 Subsequent published phase
III trials of daclizumab and ocrelizumab, as well as
the recently concluded phase III trial for ozanimod, have been conducted with active comparator arms.29,30 These trials have shown that active
comparator studies are feasible to detect both the
efficacy and superiority of new agents. On the
other hand, the use of an active comparator arm
instead of a placebo reduces on-study changes
between both groups, resulting in more patients
4

needed to observe a significant and meaningful
treatment effect. Modern-day trials have reflected
this change. Whereas early trials typically enrolled
around 200 patients, modern trials have frequently
enrolled more than 1000 patients. The increasing
costs of conducting large-scale trials have put a
strain on existing resources, and there is a need for
more efficient designs.
Combination trials
Combination trials seek to answer the question of
whether multiple therapies administered together
have greater efficacy than either alone. Studies
are designed on the premise of using different
agents with complementary or synergistic mechanisms of action.31 In this regard, the most rigorous study to date examined the effects of
glatiramer acetate and interferon β-1a administered together, which did not show a benefit in
using both drugs over the more effective agent,
glatiramer acetate.32,33 Other studies combining
DMTs with hormonal therapy34 or statins35 have
shown mixed results. Significant drawbacks of
employing combination trials include the potential antagonistic mechanisms of action among
study agents, compounded costs and side effects,
and increased size and complexity of the trial
design.36 While these reasons have deterred
journals.sagepub.com/home/tan
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combination trials in MS, there may be a role in
the future as we progress in understanding the
disease pathophysiology and developing more
therapeutic options.37
Adaptive designs
Adaptive designs offer flexible and efficient trial
methods that allow for preplanned modification of
the study protocol after an interim analysis. This
allows for flexibility in cost and trial duration. While
adaptive designs have seen use in other fields of
medicine, current experience with adaptive designs
in MS is just emerging. The phase II trial of siponimod for PMS was the first and only published MS
trial to date that employed an adaptive design to
evaluate the safety and tolerability of the study
agent and to determine its dose-efficacy response
curve.38 The study randomized one cohort of
patients to receive 10 mg, 2 mg, or 0.5 mg of the
study agent or placebo and evaluated the outcome
of combined unique active MRI lesions at month 3.
An interim analysis was performed, and based on
an estimation of which doses would be needed for
the optimum dose–response characterization, a
second cohort of patients were randomized to
receive 1.25 mg and 0.25 mg of the study drug.
Evidence for the further efficacy of siponimod was
recently published in a double-blind randomized
placebo phase III trial.39 The design of adaptive trials demands meticulous planning and a detailed
interpretation of the interim results and navigation
of a complex review process. It also requires a sensitive short-term outcome measure on which to base
interim decisions and long-term outcomes to assess
treatment efficacy. Adaptive designs for MS are
nascent and their prevalence remains to be seen.
Pragmatic trials
As therapeutic options for MS broaden, there is a
growing need for evidence demonstrating applicability of clinical trial results to routine clinical
practice. In contrast with explanatory trials, which
measure efficacy under controlled settings, pragmatic trials are designed to evaluate treatment
effectiveness in the real-world setting, producing
results that are more generalizable and applicable
to clinical practice.40 Despite the distinction
between explanatory and pragmatic trials, actual
trials fall on a spectrum between the two categories as characterized the Pragmatic–Explanatory
Continuum Index Summary (PRECIS) tool and
its subsequent revision (PRECIS-2).41,42 The tool
journals.sagepub.com/home/tan

helps trialists to ensure their design decisions
match the trial’s intended purpose.
Just as explanatory trials face the challenge of
requiring a large sample size with enough followup time to detect significant treatment effects, the
issue is even greater in pragmatic trials when
selection criteria and interventions are less controlled. A purely pragmatic trial in MS is almost
unattainable and will almost certainly include
components towards the explanatory end of the
spectrum. As adeptly summarized by Ford and
Norrie in a publication of pragmatic trials in the
New England Journal of Medicine, ‘a pragmatic
approach to pragmatism would be to adopt the
features of pragmatic trials whenever feasible and
sensible and when such features do not compromise trial quality and the ability to answer the
clinical question of interest.’43
Traditional and new outcome measures
Relevant and sensitive outcome measures are key
to the assessment of a new drug’s efficacy.
Traditionally, phase II trials assess the short-term
effects on MRI outcomes, while phase III designs
focus on more overt clinical outcomes. While this
model has standardized the development of the
currently available DMTs, the outcome measures
used are imperfect, largely due to the heterogeneity of the disease. The paradigm of the MRI in
phase II may be limited to the mechanism of
action of the DMTs; most, if not all, have
addressed inflammation as the target. New drugs
may require different measures either on MRI or
other biomarkers. Variations in disease presentation across the population and even within an
individual over time have led to challenges in the
development of methods to assess treatment efficacy. This is further complicated by the need to
capture changes within a short clinical trial duration for a disease with a prolonged clinical course.
Traditional clinical and imaging outcome measures continue to show utility in modern trials
while new measures in advanced imaging outcomes, biomarkers and composite outcomes have
diversified options for choosing study endpoints.
The advantages and disadvantages of outcomes
measures in MS trials are summarized in Table 2.
Clinical outcome measures
Clinical outcomes play an important role as the
primary endpoint of pivotal phase III trials.
5
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Table 2. Advantages and disadvantages of outcomes measurements in MS trials.
Outcome measure

Advantages

Disadvantages

EDSS

Established and universally accepted
clinical outcome measurement; familiar
to clinicians and regulators

Inter-rater variability; heavy
emphasis on walking; exclusion
of cognitive impairment;
nonlinear scale

MSFC

High reliability, validity, and sensitivity;
versatile in evaluating various levels of
disability

z-scores are abstract and difficult
to interpret

Patient-reported
outcomes

Patient-centered assessment of disease
or treatment impact

Inherently subjective; limited
use in disease-modifying therapy
efficacy trials

MRI lesions

Objective and quantifiable; High
sensitivity in detecting subclinical
disease activity; particularly useful as
primary outcome measures in phase II
trials

Lesions do not reflect degree of
clinical disability

Brain atrophy

Correlations with disability and
cognitive impairment; measurement of
neurodegeneration

Requires longer time to detect
atrophy changes; multiple
variables may confound
measurements

OCT

Fast, inexpensive, noninvasive technique;
association with neurodegeneration

Limited evaluation of central
nervous system function and
disease burden

Fluid biomarkers

Provides insight into disease
pathophysiology; detects ongoing disease
process; easy to obtain from serum

No established biomarkers;
current biomarkers lack
specificity

Combined outcomes
(NEDA-3 and NEDA-4)

Better predictive value for disability
progression than individual measures
can identify treatment response

Cannot measure specific
outcomes; no standardized set of
components

EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; MS, multiple sclerosis; MSFC, multiple
sclerosis functional composite; NEDA-3, no evidence of disease activity including absence of new lesions, confirmed EDSS
worsening and relapses; NEDA-4, as NEDA-3 in addition to absence of significant brain volume changes; OCT, optical
coherence tomography.

Assessments of relapse and changes in the EDSS
score have been the oldest and most widely used
clinical outcome measures. They each capture
distinct pathophysiologic processes of the disease.
Whereas relapse rates measure inflammatory
activity, changes in the EDSS reflect accumulation of clinical disability from inflammatory or
neurodegenerative disease processes. The EDSS
is universally familiar to MS clinicians and
accepted by regulators,44,45 but it is marked by
shortcomings in its variability between examiners,
heavy emphasis on walking, limited impact of cognitive impairment and nonlinearity. The imperfections of the EDSS have led to the development
of the MS functional composite (MSFC),46 which
6

covers three major MS domains, can be assessed
quickly and reliably, and gives a z-score on a continuous scale. However, z-scores are abstract and
difficult to interpret clinically, which has limited
the widespread use of the MSFC. Despite its
imperfections, the EDSS currently remains the
most accepted clinical outcome measure and will
likely remain so for the near future. Recently, electronic scoring of the EDSS has been developed
and has shown an increased consistency of EDSS
scoring,47 and it has seen use in the phase III trials
of ocrelizumab30 and siponimod.39
Over the past decade, patient-reported outcome
(PRO) measures have increasingly been used as
journals.sagepub.com/home/tan
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complements to objective clinical measures and
provide important information on subjective outcomes, such as evaluations of subjective symptoms, satisfaction with treatment, and quality of
life.48–50 They offer an additional facet in the
assessment of treatment risks and benefits.
Nevertheless, the subjectivity of PROs typically
limits their use to a secondary outcome measure
for DMT investigations.51 Their use as primary
outcomes for symptomatic therapies may be
appropriate.
Neuroimaging outcome measures
Neuroimaging outcome measures provide additional information to supplement clinical measurements of treatment efficacy. Most commonly
used are MRI measurements of lesion load or
atrophy, which provide objective and highly sensitive measurements of current and past disease
activity. Inflammatory activity can be quantified
as focal lesions on T2 MRI sequences or T1 gadolinium-enhancing lesions and have shown a correlation with relapse rate.52,53 This important
metric has allowed for rapid development of
DMTs for RRMS due to its use as the primary
outcome in short-term phase II trials. The ability
to detect reductions in lesions on MRI associated
with treatment allows for quick progress into
phase III trials.54 The accrual of disability as
reflected by neurodegeneration is measured by
brain atrophy. This has been commonly assessed
either as total brain parenchymal volume or fractional volume, defined as the ratio of brain parenchymal volume to total volume within the brain
surface contour.
MRI outcome measurements have undergone
refinement as the understanding of the disease
process continues to develop. Composite imaging
outcomes of combined unique active lesions have
seen use in a growing number of trials to assess
total new or enlarging T2 or gadolinium-enhancing lesions. Regional atrophy is increasingly
explored as a more sensitive measurement of
changes reflective of associated deficits, and areas
of the thalamus and cerebellum may be more sensitive to changes.55,56 Gray matter atrophy has been
shown to have more clinical correlation than white
matter atrophy and is more sensitive to changes.57
Optical coherence tomography (OCT) is a noninvasive method to image the retina and characterize pathology of the optic nerve.58 By visualizing
journals.sagepub.com/home/tan

the unmyelinated axons of the retinal nerve fiber
layer (RNFL), OCT can directly assess axonal
injury. In MS patients, the RNFL is thinner than
in healthy people, regardless of a previous history
of optic neuritis, supporting its role as a unique in
vivo model of neurodegeneration.59–62 OCT has
been used as an outcome measure in a few clinical
trials in PMS without evidence of neuroprotective
effects.63–66 Despite its current lack of prevalence
in clinical trials, OCT as a fast, inexpensive, and
noninvasive approach to evaluate neurodegeneration, continues to prompt further investigation
into refining the method.
Advancements in imaging techniques have led to
the development of new outcome measures.
Magnetization transfer ratio (MTR) is an MRI
technique used to assess tissue integrity by correlating it with axonal loss in MS lesions. Whole
brain MTR has been used in several trials,28,63,64,67,68 while regional MTR has been used
in the phase III trial of laquinimod for RRMS.69
While imaging outcome measurements are not
likely to replace clinical endpoints in trials, they
provide important information that supplements
data on the efficacy of novel agents.
Fluid biomarkers
Clinical and radiologic outcome measures have
served as the cornerstone of assessing the therapeutic efficacy of drugs and disease activity; however, they provide limited assessment of the
pathophysiological disease process, such as inflammation, axonal injury, and demyelination. Early
search for biomarkers in the spinal fluid of MS
patients hoped to identify outcomes that could be
used in trials, but these efforts have not yielded
promising results. In recent years, several biomarkers for MS have shown potential for diagnosis,
prognosis, monitoring disease activity and treatment response.70 Although currently there are no
established biomarkers in use in clinical trials,
among the most promising is neurofilament light
chain (NFL).71 NFL is a subunit of neurofilaments
that compose the axonal and dendritic cytoskeleton. It is released during axonal injury, making it a
marker of axonal damage.72 In addition to its presence in the cerebrospinal fluid, NFL can also be
detected in the serum due to using the ultrasensitive single molecule array (Simoa) technology.73,74
Serum NFL has been shown to correlate with
relapses, EDSS scores, MRI lesions, and brain and
spinal cord atrophy,75–78 and its levels have shown
7
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a decrease in patients treated with DMTs.79–82 Its
downside is the lack of specificity, and levels may
be influenced by many comorbidities or conditions. With an increased availability and understanding of NFL and disease activity, NFL may
become the first fluid biomarker to be used to
monitor therapeutic effects in future randomized
clinical trials and we may eventually see its use in
the clinical setting.
Combined outcome measures
Other new outcome measures have integrated
domains to achieve a more holistic evaluation.83
The concept of disease activity-free status in MS
was first explored in the natalizumab phase III
trial,84 and it was later defined as ‘no evidence of
disease activity’ (NEDA) to reflect the absence of
relapses and no progression of disability or new
MRI activity. NEDA has been used in some phase
II85,86 and phase III trials.20,21,32 The combination
of outcome measures increased the predictive
value of disability progression compared with individual clinical or MRI metrics.87 The drawback of
using NEDA lies in the inability to assess its effects
on specific outcomes, since clinical and radiological activity are all combined into one assessment
that is heavily dependent on timing. Currently,
NEDA is still undergoing refinement as it remains
unclear which optimal components to include and
how frequently they should be assessed. In addition, brain volume as a marker of neurodegeneration has been proposed to be included in a revised
measure referred to as NEDA-4.88 As the concept
of NEDA continues to evolve, it becomes important to establish standardized definitions to facilitate universal interpretation and demonstrate its
validity and reliability across studies.
Clinical trials for progressive MS
While substantial progress has been made in the
advancement of therapeutic options for RRMS,
progress for PMS remains limited and treatments
are much needed, and only recently has a DMT
been approved for PMS.89 The challenges in
advancing therapeutics in PMS arise from a limited understanding of the pathogenesis of PMS
and difficulty defining and assessing the disease
course, as well as apparent confounding with the
aging process. This contrasts with the established
trial methodology for RRMS in which changes in
focal MRI lesions in phase II trials allow for the
accurate prediction of clinical reductions in relapse
8

rate in phase III trials. Trials for PMS do not have
established enrollment criteria owing to the lack of
a uniform clinical definition of the disease.90
Currently, there are no sensitive markers of disease
activity that can accurately capture the varying
degrees of inflammatory activity in the setting of
neurodegeneration. Due to the process of neurodegeneration and compartmentalized inflammation playing a key role in PMS, drugs with
predominantly systemic anti-inflammatory activity
are less likely to be effective, especially in older
patients where inflammatory activity has declined.
There is a heightened focus on clinical trials for
PMS. Recently, The European Committee for
Treatment and Research in MS (ECTRIMS) in
association with the International Progressive MS
Alliance held a workshop to address strategies for
the advancement of trial design in PMS.91,92 The
workshop addressed multiple aspects of trials for
PMS and proceedings were published as a series of
review articles in a themed issue of the Multiple
Sclerosis Journal. The group recognized the growing importance of people with PMS in providing
feedback and marketing and even in the design of
trials.93 Patients now undertake a larger role than
just participating in volunteer trials. They are
involved in providing feedback in developing more
clinically meaningful outcome measurements,
advocating financial support, and serving as representatives in the trial’s development committees.
The group recognized the pathophysiology of
PMS as playing a key role in the trial design and
therapy selection. The pathophysiology of PMS
differs from RRMS in which systemic inflammation progresses to compartmentalized inflammation and neurodegeneration. The dynamic
changes in pathophysiology over the course of the
disease highlights the importance of identifying
the disease stage and timing of intervention.
Drugs with anti-inflammatory properties will
have more benefit in patients with active inflammation and are less effective in patients who have
reached the late stages of neurodegeneration.94
Enrollment of patients who have more active
disease progression will likely have a greater
sensitivity in detecting the treatments measuring
progression than patients who do not progress.
However, too narrow inclusion criteria will compromise the external validity and generalizability
of results. More research to understand the
pathophysiology and population characteristics of
PMS are underway.
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Due to a current lack of early and sensitive measurements of disease progression in PMS, an
emphasis was placed on outcome measures.
Clinical outcome measures such as the EDSS
continue to serve as the established benchmark in
PMS trials, but the shortcomings of EDSS limit
its use alone as a sufficient outcome because of its
near exclusive reliance in its upper ranges on
walking and ignoring important functions such as
cognitive and arm functions. Other measures
have begun to surface that assess the vital clinical
components of PMS. Together, these outcome
measures address multiple facets of the clinical
experience and are shaping trials to include a
reworking and integration of new metrics such as
composite measurements, cognition, and PROs.95
The lack of a sensitive phase II trial outcome
measure poses a limit to the timely advancement
of potential therapeutic agents beyond their
proof-of-concept phase. This contrasts with phase
II trials for RRMS that employ focal MRI lesions
to detect short-term changes. Currently, whole
brain atrophy is the most accepted phase II outcome measurement in PMS.96 However, there
are notable limitations including slowness to
change, inter-patient variability, and unidimensional measurement. Other biomarkers in development and testing, such as NFL, have begun to
show promise.97
Despite challenges in PMS trials, there is progress
in recent trials that have shown a positive effect in
PMS including simvastatin,98 biotin,99 ocrelizumab,89 and siponimod.39 Potential evolution in
the trials in PMS will focus on identifying agents
targeting neuroprotection and remyelination,
carefully identifying a study population with
regards to baseline inflammatory activity, choosing accurate and sensitive outcome measures in
both phase II and III trials, and exploring the
potential of adaptive designs.
Conclusion
The past 25 years have witnessed substantial
developments in the treatment of MS.
Advancements in therapeutic agents are a direct
result of clinical trials that demonstrated their
efficacy. Just as the disease course has been redefined with the advent of DMTs, so have characteristics of trials that continue to test new agents.
The present-day MS trial population no longer
shares the same baseline characteristics as historical groups and is distinguished by earlier
journals.sagepub.com/home/tan

diagnosis and milder disease presentation due to
increased availability of treatment. This change
is present even in placebo groups, thus complicating the comparison of data across trials. At
the same time, active comparator designs have
replaced placebo-controlled trials for RRMS, as
the latter is no longer ethical in an era of proven
therapeutic options. The head-to-head comparison of two agents has increased the required trial
sample size and duration to be able to detect significant on-study differences. This has motivated consideration of more efficient study
designs such as adaptive designs that have the
potential to seamlessly transition from phase II
to phase III trials, thus reducing the cost and
expediting the trial process.
At the same time, new options for clinical and
neuroimaging outcome measurements are beginning to see use in trials to capture different aspects
of the disease process. While traditional measures
of relapse (e.g. changes in EDSS and focal MRI
lesions) continue to remain the standard of assessment of disease activity, new parameters such as
brain volume, PROs, MTR, OCT, NFL have
contributed new dimensions to capturing disease
progression.
Amidst the successful development of DMTs for
RRMS, increasing focus has turned towards clinical trials for PMS where current therapies are
limited and much needed. Experience with PMS
trials has identified challenges in study design
inherent in the nebulous characterization of the
disease course and lack of sensitive measurements
of disease progression. Unlike in RRMS where
inflammatory activity can be assessed by relapses
and lesion changes on MRI, there is no sensitive
equivalent in measuring neurodegeneration and
compartmentalized inflammation, which constitutes significant mechanisms in the pathophysiology of PMS. Nevertheless, recent research has
shown positive results in multiple agents for the
treatment of PMS, and outcome measures such
as brain atrophy is an acceptable metric of neurodegeneration. Various agents in remyelination
and neuroprotection are currently being tested,
and the potential applications of adaptive designs
are being explored.
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